Presentations

Date	Title
Apr 10, 2023	Omeros Complement Programs 4.7 MB
Dec 12, 2022	ASH 2022: Trial in Progress: An Open-Label, Multi-Center Phase 2 Study Evaluating Efficacy and Safety of the MASP-2 Inhibitor Narsoplimab in Pediatric Patients with High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy 348.3 KB
Dec 11, 2022	ASH 2022: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Alternative Pathway MASP-3 Inhibitor OMS906 in a Phase 1 Study of Healthy Subjects 362.9 KB

You are now leaving Omeros.com